drug

Clinical-stage biotech company Pfenex gets FDA's approval for PF708. Pfenex is conducting a comparative study between PF708 and Eli Lilly's Forteo and will submit the final study report to FDA later this month.

I smoke every night to sleep, does intuitive surgical drug test for a developer position?

Last week, Gilead failed in Phase 3 clinical trial for NASH drug. Today, Intercept has become the first player in the NASH area to complete a pivotal Phase 3 study in patients with liver fibrosis.

For those of you who are new hires in California what was the physical/drug screen like? Was it a Urine or Hair test? Thank you!

Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/

United Therapeutics signs an agreement with Arena in a deal worth $1.2 billion. It will pay $800 million as upfront payment to Arena and $400 million as potential milestone payments. This is what exactly Arena investors have been looking for. This will be a win-win deal for both the companies...

Shares of biotech company Biogen (BIIB) rallied on Thursday during the after-hours trading after the company said it achieved positive results from final analysis of its Phase II trial of an Alzheimer’s drug. The advanced drug candidate, BAN2401, was developed in partnership with a Tokyo-based...

Does Regeneron drug test interns not on the clinical side?

Upping its ante against its rivals in the medical and pharma sector, Walgreens has finally completed its acquisition of Rite Aid’s stores for $4.4billion. The deal brings 1,932 Rite Aid stores as well as three distribution centers under the umbrella of Walgreens. Though Walgreens initially...

AbbVie’s soon-to-become next blockbuster drug ELAGOLIX meet phase III trial target. Source: https://news.alphastreet.com/abbvies-elagolix-meet-phase-iii-trial-target/

Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since the year started. But is it time to get rid of the world’s largest pharma company’s shares? Let’s see.

Privately-held Albertsons Companies is planning to buy the portion of Rite Aid that is not being sold to Walgreens Boots Alliance. The combined value of Albertsons and Rite Aid, including debt, is around $24 billion. The proposed cash-and-stock deal will give Albertsons shareholders ownership...

Johnson&Johnson is discontinuing clinical trials on two potentially blockbuster drugs. Bad timing I would say. I wonder how the company plans to maintain its growth in Pharma sales without these drugs. Source Article

While I was expecting this fate for sirukumab after Glaxo abandoned its partnership on this drug, talacotuzumab's discontinuation was totally unexpected. Two drugs that were so needed! Article source